Some Indirect Claims Stay In Aggrenox Pay-For-Delay Row
A Connecticut federal judge on Tuesday kept alive some antitrust claims by Humana Inc., employee health funds and other indirect purchasers of blood-clot medication Aggrenox in multidistrict litigation that accuses Teva...To view the full article, register now.
Already a subscriber? Click here to view full article